Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom.
Cost analysis
Lurasidone
Schizophrenia
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
25 Aug 2022
25 Aug 2022
Historique:
received:
04
01
2022
accepted:
04
08
2022
entrez:
24
8
2022
pubmed:
25
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Schizophrenia is a serious mental health condition characterised by distortions in thought processes, perception, mood, sense of self, and behaviour. Lurasidone, a second-generation atypical antipsychotic, represents an additional treatment option alongside existing antipsychotics for adolescents and adults with schizophrenia. An economic model was developed to evaluate the incremental costs of lurasidone as a first-line treatment option compared to existing antipsychotics. A Markov model was developed to estimate the cost impact of lurasidone as a first-line treatment option for both adolescents and adults. The sequence-based model incorporated the following health states: stable (no relapse or discontinuation), discontinuation (due to adverse events or other reasons), and relapse. Data used to determine the movement of patients between health states were obtained from network meta-analyses (NMAs). The time horizon ranged from three to five years (depending on the patient population) and a six-weekly cycle length was used. Unit costs and resource use were reflective of the UK NHS and Personal Social Services and consisted of the following categories: outpatient, adverse events, primary and residential care. Extensive deterministic sensitivity analysis was undertaken to assess the level of uncertainty associated with the base case results. Lurasidone is demonstrated to be cost-saving as a first-line treatment within the adolescent and adult populations when compared to second-line and third-line respectively. Lurasidone is more expensive in terms of treatment costs, resource use (in the stable health state) and the treatment of adverse events. However, these costs are outweighed by the savings associated with the relapse health state. Lurasidone remains cost-saving when inputs are varied in sensitivity analysis and scenario analysis. Lurasidone is a cost-saving first-line treatment for schizophrenia for both adolescents and adults.
Sections du résumé
BACKGROUND
BACKGROUND
Schizophrenia is a serious mental health condition characterised by distortions in thought processes, perception, mood, sense of self, and behaviour. Lurasidone, a second-generation atypical antipsychotic, represents an additional treatment option alongside existing antipsychotics for adolescents and adults with schizophrenia. An economic model was developed to evaluate the incremental costs of lurasidone as a first-line treatment option compared to existing antipsychotics.
METHODS
METHODS
A Markov model was developed to estimate the cost impact of lurasidone as a first-line treatment option for both adolescents and adults. The sequence-based model incorporated the following health states: stable (no relapse or discontinuation), discontinuation (due to adverse events or other reasons), and relapse. Data used to determine the movement of patients between health states were obtained from network meta-analyses (NMAs). The time horizon ranged from three to five years (depending on the patient population) and a six-weekly cycle length was used. Unit costs and resource use were reflective of the UK NHS and Personal Social Services and consisted of the following categories: outpatient, adverse events, primary and residential care. Extensive deterministic sensitivity analysis was undertaken to assess the level of uncertainty associated with the base case results.
RESULTS
RESULTS
Lurasidone is demonstrated to be cost-saving as a first-line treatment within the adolescent and adult populations when compared to second-line and third-line respectively. Lurasidone is more expensive in terms of treatment costs, resource use (in the stable health state) and the treatment of adverse events. However, these costs are outweighed by the savings associated with the relapse health state. Lurasidone remains cost-saving when inputs are varied in sensitivity analysis and scenario analysis.
CONCLUSIONS
CONCLUSIONS
Lurasidone is a cost-saving first-line treatment for schizophrenia for both adolescents and adults.
Identifiants
pubmed: 36002828
doi: 10.1186/s12913-022-08436-x
pii: 10.1186/s12913-022-08436-x
pmc: PMC9404623
doi:
Substances chimiques
Antipsychotic Agents
0
Lurasidone Hydrochloride
O0P4I5851I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1084Informations de copyright
© 2022. The Author(s).
Références
Neuropsychiatr Dis Treat. 2021 Jan 20;17:125-137
pubmed: 33505160
NPJ Schizophr. 2018 Jun 27;4(1):12
pubmed: 29950586
J Psychopharmacol. 2020 Jan;34(1):3-78
pubmed: 31829775
Mol Psychiatry. 2012 Dec;17(12):1206-27
pubmed: 22584864
Mol Psychiatry. 2009 Apr;14(4):429-47
pubmed: 18180760
Mol Psychiatry. 2013 Jan;18(1):53-66
pubmed: 22124274
Cochrane Database Syst Rev. 2013 Nov 15;(11):CD003082
pubmed: 24242360
Pharmacoeconomics. 2016 Jul;34(7):709-21
pubmed: 27067724
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
Sci Rep. 2021 Mar 10;11(1):5571
pubmed: 33692392
BJPsych Open. 2016 Feb 5;2(1):59-66
pubmed: 27703755
Epidemiol Rev. 2008;30:67-76
pubmed: 18480098